Sign in

NVNO on Nasdaq

enVVeno Medical Corp

EnVVeno Medical Corp is an American surgical and medical instruments and apparatus company based in Irvine.2 Its shares trade on Nasdaq under the symbol NVNO.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Odyssey Health, Inc., ALR Technologies SG Ltd. or VIVOS INC, or pick any stock.

  • TickerNVNO on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersIrvine, United States2
  • Incorporated inDE3
  • Business address70 Doppler, Irvine, Ca 926183
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KF5KREFECSNV872
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 31471202

See how the biggest companies compare on our leaderboards

Each valve is supposed to open as blood passes through, and then close as blood progresses up the veins of the leg to the next valve.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-24566.5%Operating margin5
-24406.7%Net margin5
-770.3%Return on equity6
-$6.3MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2019

  • Research and development31¢$2.2M
  • Selling, general and admin69¢$4.9M

Out of $31.2K in revenue.5 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development expenses$10.0M$12.2M
Selling, general and administrative expenses$10.9M$11.6M
Loss from operations-$20.9M-$23.8M
Realized gain from sales of trading securities$1.1M$1.6M
Unrealized loss from trading securities-$391.0K-$22.0K
Interest income$692.0K$389.0K
Total other income$1.4M$2.0M
Net loss-$19.5M-$21.8M
Net loss per basic common share-$33.06-$44.53
Net loss per diluted common share-$33.06-$44.53
Basic589.0K shares490.0K shares
Diluted589.0K shares490.0K shares

Compare enVVeno Medical Corp with another company

Corporate structure

enVVeno Medical Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of enVVeno Medical Corp

  • enVVeno Medical Corp Irvine, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What enVVeno Medical Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.4M9 Dec 31, 2025$1.4M9 Dec 31, 2024+0.3%
Accumulated depreciation$1.4M9 Dec 31, 2025$1.3M9 Dec 31, 2024+10.8%
Property and equipment, net$51.0K9 Dec 31, 2025$182.0K9 Dec 31, 2024−72.0%
Operating-lease assets (leased space)$654.0K9 Dec 31, 2025$1.0M9 Dec 31, 2024−35.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.1M9 Dec 31, 2025$1.8M9 Dec 31, 2024+74.7%
Marketable securities, current$25.1M9 Dec 31, 2025$41.4M9 Dec 31, 2024−39.3%

Properties, in its own words

As of December 31, 2025, we lease a 14,507 square foot manufacturing facility in Irvine, California under a lease that expires on September 30, 2027. Our facility is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development, prototype fabrication, cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices. We believe that our facilities are sufficient for the near future as there is present capacity to manufacture up to approximately 20,000 venous valves per year to meet potential market demands.

Item 2 of the 10-K filed Mar 26, 2026.4

Leadership

Who has led enVVeno Medical Corp, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Robert A. Rankin2018
  2. Craig Glynn2021–2023
  3. Jennifer Bright2025–now
20202025
Board members and other officers (11)

Former names

  • Hancock Jaffe Laboratories, Inc.Dec 15, 2015 to Sep 22, 20213

Timeline

  1. Jul 14, 20268-K Regulation FD disclosure24
  2. Apr 29, 20268-K Results of operations; Regulation FD disclosure; Other events25
  3. Feb 4, 20268-K Results of operations; Other events26
  4. Jan 20, 20268-K Bylaws or fiscal year changed27
  5. Dec 12, 20258-K Shareholder vote28
  6. Nov 20, 20258-K Bylaws or fiscal year changed29
  7. Nov 14, 20258-K Regulation FD disclosure30
  8. Oct 30, 20258-K Entered a material agreement31
  9. Oct 10, 20258-K Listing notice or transfer32
  10. Aug 20, 20258-K Regulation FD disclosure33
  11. May 20, 20258-K Executive or director change34
  12. Apr 21, 20258-K Change of auditor35
  13. Dec 22, 1999Founded enVVeno Medical Corp is founded2

Calendar

Coming up

  1. Oct 30, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($8.07) a share, on Oct 31, 2025.36

When it reported results

  1. Apr 29, 2026Reported quarterly or annual results25
  2. Feb 4, 2026Reported quarterly or annual results26

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

163 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 23 major events, 55 insider forms, 22 large holders, 40 other. The latest 20:

  1. Sep 15, 2026SCHEDULE 13D/A EDGAR
  2. Sep 14, 20264 EDGAR
  3. Sep 11, 2026144 EDGAR
  4. Aug 21, 2026S-3 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Jul 30, 202610-Q EDGAR
  7. Jul 14, 20268-K EDGAR
  8. Jun 12, 20264 EDGAR
  9. Jun 11, 2026144 EDGAR
  10. May 15, 2026SCHEDULE 13G/A EDGAR
  11. May 15, 2026SCHEDULE 13G/A EDGAR
  12. May 6, 202610-Q EDGAR
  13. Apr 29, 20268-K EDGAR
  14. Mar 26, 2026S-8 EDGAR
  15. Mar 26, 202610-K EDGAR
  16. Mar 13, 20264 EDGAR
  17. Mar 12, 2026144 EDGAR
  18. Feb 20, 2026SCHEDULE 13D EDGAR
  19. Feb 20, 2026SCHEDULE 13D EDGAR
  20. Feb 17, 2026SCHEDULE 13G/A EDGAR

The 163 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 10 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026Duhay FrancisDirectorSale11$11.21$123Form 4
Jun 11, 2026Duhay FrancisDirectorSale140$10.31$1.4KForm 4
Mar 12, 2026Duhay FrancisDirectorSale140$11.52$1.6KForm 4
Dec 11, 2025Duhay FrancisDirectorSale4,900$0.36$1.8KForm 4
Sep 15, 2025Duhay FrancisDirectorSale4,900$0.83$4.1KForm 4
Dec 31, 2024Duhay FrancisDirectorBuy81,433$3.07$250.0KForm 4
Dec 31, 2024Gray RobertDirectorBuy3,500$2.94$10.3KForm 4
Dec 24, 2024Shrivastava SanjayDirectorBuy5,400$2.90$15.7KForm 4
Dec 19, 2024Jenusaitis MatthewDirectorBuy9,620$2.53$24.3KForm 4
Dec 19, 2024BERMAN ROBERT ANDREWChief Executive OfficerBuy12,000$2.55$30.6KForm 4
Mar 13, 2024Alavi HamedChief Technology OfficerSale8,334$6.22$51.8KForm 4
Aug 16, 2022Duhay FrancisDirectorBuy7,751$6.14$47.6KForm 4
Jun 30, 2022Shrivastava SanjayDirectorBuy1,000$3.85$3.9KForm 4
Jun 27, 2022BERMAN ROBERT ANDREWChief Executive OfficerBuy2,500$3.80$9.5KForm 4
Nov 19, 2021BERMAN ROBERT ANDREWChief Executive OfficerBuy2,000$7.43$14.9KForm 4
Nov 16, 2021BERMAN ROBERT ANDREWChief Executive OfficerBuy2,000$7.87$15.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Robert A. BermanChief Executive Officer62$500.0K$1.2M46
2024Marc H. Glickman, M.D.Chief Medical Officer and Senior Vice President76$367.5K$626.6K46
2024Dr. Hamed AlaviSenior Vice President & Chief Technology Officer42$300.0K$521.9K46
2024Craig GlynnChief Financial Officer$250.0K$302.2K46
2023Robert A. BermanChief Executive Officer62$500.0K$1.9M46
2023Marc H. Glickman, M.D.Chief Medical Officer and Senior Vice President76$367.5K$776.4K46
2023Dr. Hamed AlaviSenior Vice President & Chief Technology Officer42$300.0K$669.2K46
2023Craig GlynnChief Financial Officer$250.0K$527.3K46

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kingdon Capital Management, L.l.c.36,166$387.3K0.1%No change
CM Management, LLC35,714$382.5K0.2%No change
Vanguard Capital Management LLC6,287$67.4K0.0%No change
Jpmorgan Chase & Co5,208$59.1K0.0%−1
Vanguard Fiduciary Trust Co2,184$23.4K0.0%No change
Westside Investment Management, Inc.1,525$16.3K0.0%−64
Mirae Asset Global Investments Co., Ltd.539$5.8K0.0%New
BlackRock, Inc.414$4.4K0.0%−1,426
Tower Research Capital LLC (TRC)331$3.5K0.0%−211
Wells Fargo & Company/mn114$1.2K0.0%No change
Allied Private Wealth LLC88$9780.0%New
Vanguard Global Advisers, LLC77$8250.0%No change
Morgan Stanley59$6320.0%−17
Osaic Holdings, Inc.7$740.0%No change
Barclays PLC2$210.0%New
Group One Trading LLC2$210.0%No change
UBS Group AG1$110.0%−242

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How enVVeno Medical Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARenVVeno Medical Corp1
  • CIK0001661053
  • Employer ID (EIN)33-09361804
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address70 Doppler, Irvine, CA 926181
  • Phone949-261-29001
  • Shares outstanding682,722 as of Jul 28, 20268
  • Public float$76.1M as of Jun 30, 20254
  • AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 199; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 15, 20151
  • Filings412 in all: 4 (86), 8-K (57), CORRESP (28), 10-Q (25), 3 (21), UPLOAD (20), EFFECT (15), S-1/A (14)1
    All 47 form types

    144 (12), SC 13G/A (11), SC 13G (10), DEF 14A (9), FWP (9), 10-K (8), 424B5 (8), S-1 (8), D (6), S-3 (6), S-8 (6), SCHEDULE 13G/A (6), 424B4 (5), SCHEDULE 13G (4), 3/A (3), 424B3 (3), S-3/A (3), 10-K/A (2), 4/A (2), DEFA14A (2), DRS (2), POS AM (2), S-1MEF (2), SCHEDULE 13D (2), 10-Q/A (1), 25-NSE (1), 5 (1), 8-A12B (1), 8-A12B/A (1), 8-K/A (1), CERT (1), D/A (1), DEFR14A (1), NT 10-Q (1), PRE 14A (1), PRER14A (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) Jul 30, 2026
    Proxy statement (DEF 14A) Oct 30, 2025
    Latest 8-K (8-K) Jul 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.00001 par valueNVNONASDAQ

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks enVVeno Medical Corp names in Item 1A of its 10-K filed Mar 26, 2026: 36 risks under these headings, as written.4

  • Risks Related to Our Business and Strategy
  • We have incurred losses since our inception, expect to incur losses in the future and may never achieve or sustain profitability.
  • We currently depend entirely on the successful and timely regulatory approval and commercialization of our current product candidate, and any future product candidates, which may not receive regulatory approval or, if any of our product candidates do receive regulatory approval, we may not be able to successfully commercialize them.
  • If we are unable to successfully raise additional capital, our future clinical trials and product development could be limited and our long-term viability may be threatened.
  • We may never be able to generate sufficient revenue from the commercialization of our product candidates to achieve and maintain profitability.
  • We only utilize a few suppliers for porcine tissue for our product candidates and the loss of a supplier could have an adverse impact on our business.
  • We depend upon third-party suppliers for certain components of our product candidates, making us vulnerable to supply problems and price fluctuations, which could harm our business.
  • If we successfully develop product candidates, which at this time will likely take several years at a minimum, we will have to demonstrate the efficacy and financial viability of our products to doctors, hospitals, insurance companies, and other stakeholders.
  • We may be unable to convince hospital facilities to approve the use of our product candidates.
  • We face significant competition and our business prospects will depend on our ability to develop and commercialize our current product candidates and may also depend on our ability to develop additional product candidates.
  • If we are unable to produce an adequate supply of our product candidates for use in our current and planned clinical trials or for commercialization because of our limited manufacturing resources or our facility is damaged or becomes inoperable, our regulatory, development and commercialization efforts may be delayed.
  • We currently have no sales and limited marketing infrastructure and we may not be able to build a sales and marketing infrastructure sufficient for us to commercialize our current product candidate or future product candidates, if approved, and may be unable to do so or may never generate sufficient revenue to achieve or sustain profitability.
The other 25 risks
  • Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing product candidates and limit commercialization of any products that we may develop.
  • The loss of our executive officers or our inability to attract and retain qualified personnel may adversely affect our business, financial conditions and results of operations.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Risks Related to Regulatory Approval and Other Governmental Regulations
  • Our business and product candidates are subject to extensive governmental regulation and oversight, and our failure to comply with applicable regulatory requirements could harm our business.
  • The Company received a not-approvable letter from the FDA.
  • Our product candidates will be subject to extensive governmental regulation in foreign jurisdictions, such as the EEA, and our failure to comply with applicable requirements could cause our business, results of operations and financial condition to suffer.
  • The FDA regulatory approval, clearance and license process is complex, time-consuming and unpredictable.
  • Even if our product candidates are approved by regulatory authorities, if we fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our product candidates, our product candidates could be subject to restrictions or withdrawal from the market.
  • We are required to report certain malfunctions, deaths and serious injuries associated with our products once approved by regulatory bodies, which can result in voluntary corrective actions or agency enforcement actions.
  • Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for product candidates or to manufacture, market or distribute product candidates after clearance or approval is obtained.
  • We are subject to federal, state and foreign healthcare laws and regulations, and a finding of failure to comply with such laws and regulations could have a material and adverse effect on our business.
  • Regulatory healthcare reform measures and other legislative changes may have a material and adverse effect on business, results of operations and financial condition.
  • Our relationships with physician consultants, owners and investors could be subject to additional scrutiny from regulatory enforcement authorities and could subject us to possible administrative, civil or criminal sanctions.
  • Our company and many of our collaborators and potential collaborators are required to comply with the Federal Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act and implementing regulation affecting the transmission, security and privacy of health information, and failure to comply could result in significant penalties.
  • We are currently, and in the future may be, subject to various governmental regulations related to the manufacturing of product candidates, and we may incur significant expenses to comply with, experience delays in our product commercialization as a result of and be subject to material sanctions if we or our contract manufacturers violate these regulations.
  • Risks Related to Our Intellectual Property
  • If we are unable to adequately protect our proprietary technology or obtain and maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which could harm our business, financial condition and results of operations.
  • Obtaining and maintaining our patent protection depends on compliance with various procedures, document submission requirements, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology.
  • Risks Related to Ownership of Our Securities
  • The trading price of our securities has been and is likely to continue to be volatile and could be subject to wide fluctuations in response to a variety of factors.
  • We have issued a significant number of options and warrants and may continue to do so in the future. The vesting and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.
  • We will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and can be expected to dilute current stockholders’ ownership interests.
  • Future sales or issuances of substantial amounts of our common stock could result in significant dilution.
  • Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our Common Stock.
  • Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, which could make it more difficult for you to change management.
  • We do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46